Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
The present invention relates to methods for preventing or treating of metabolic disorders and related conditions, such as in certain patient groups.
1. A method for treating type 2 diabetes mellitus in a patient in need thereof, wherein the patient has type 2 diabetes and has at least one T allele in the single nucleotide polymorphism (SNP) rs7903146 in the gene coding for TCF7L2,
said method comprising testing whether the type 2 diabetes patient has at least one T allele in the single nucleotide polymorphism (SNP) rs7903146 in the gene coding for TCF7L2, and
administering a DPP-4 inhibitor selected from linagliptin, sitagliptin, vildagliptin, alogliptin, saxagliptin, teneligliptin and dutogliptin, and, optionally, a second antidiabetic agent selected from biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, and, optionally, a third antidiabetic agent selected from biguanides, thiazolidindiones, sulfonylureas, glinides, inhibitors of alpha-glucosidase, GLP-1 or GLP-1 analogues, and insulin or insulin analogues, to the patient, optionally in combination, including in alternation.
2. The method according to claim 1 wherein the patient has insufficient glycemic control despite diet and exercise, or despite monotherapy with the second or the third antidiabetic agent.
3. The method according to claim 1 wherein the patient has insufficient glycemic control despite diet and exercise, or despite dual therapy with the second and the third antidiabetic agent.
4. The method according to claim 1 wherein the patient has insufficient glycemic control despite diet and exercise, or despite monotherapy with either the DPP-4 inhibitor or the second or third antidiabetic agent, or despite dual therapy with the second and the third antidiabetic agent.
5. The method according to claim 1 wherein the patient has insufficient glycemic control despite diet and exercise, or despite monotherapy with either the DPP-4 inhibitor, the second or the third antidiabetic agent, or despite combination therapy with two agents selected from the group of the DPP-4 inhibitor, the second and the third antidiabetic agent.
6. The method according to claim 1 wherein the patient is diagnosed for, has been diagnosed with, or carries two T alleles of SNP rs7903146 of TCF7L2.
7. The method according to claim 1 wherein the patient is diagnosed for, has been diagnosed with, or carries one T allele of SNP rs7903146 of TCF7L2.
8. The method according to claim 1 wherein the DPP-4 inhibitor is linagliptin.
9. The method according to claim 1 wherein the DPP-4 inhibitor is linagliptin, and the second antidiabetic agent is metformin or pioglitazone.